Vitamin E pretreated Wharton's jelly-derived mesenchymal stem cells attenuate CCl
Animals
Carbon Tetrachloride
/ toxicity
Cells, Cultured
Coculture Techniques
Hepatocytes
/ drug effects
Liver Cirrhosis
/ chemically induced
Male
Mesenchymal Stem Cell Transplantation
/ methods
Mesenchymal Stem Cells
/ drug effects
Rats
Rats, Sprague-Dawley
Vitamin E
/ administration & dosage
Wharton Jelly
/ cytology
Fibrosis
Hepatocytes
Pretreatment
Vitamin E
Wharton’s jelly-derived mesenchymal stem cells
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
03
11
2020
revised:
02
02
2021
accepted:
16
02
2021
pubmed:
23
2
2021
medline:
1
7
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
Oxidative microenvironment in fibrotic liver alleviates the efficacious outcome of mesenchymal stem cells (MSCs)-based cell therapy. Recent evidence suggests that pharmacological pretreatment is a rational approach to harness the MSCs with higher therapeutic potential. Here, we investigated whether Vitamin E pretreatment can boost the antifibrotic effects of Wharton's jelly-derived MSCs (WJMSCs). We used rat liver-derived hepatocytes injured by CCl
Identifiants
pubmed: 33617844
pii: S0006-2952(21)00076-9
doi: 10.1016/j.bcp.2021.114480
pii:
doi:
Substances chimiques
Vitamin E
1406-18-4
Carbon Tetrachloride
CL2T97X0V0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
114480Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.